Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically ...
Earlier this week, Merck announced that its pivotal Phase 3 TroFuse-005 trial showed sacituzumab tirumotecan significantly ...
“Following the positive results in the endometrial cancer cohort of DESTINY-PanTumor02, which contributed to a tumor agnostic approval for previously treated patients with HER2 positive metastatic ...
A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia Estrogen receptor ...
Merck & Co. Inc. (NYSE:MRK) is one of the best low risk stocks to buy in 2026. On May 18, Merck announced that its pivotal ...
AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by AstraZeneca in the DESTINY-Endometrial01 phase 3 trial. AstraZeneca is ...
The latest trial of a new antibody drug that delivers potent chemotherapy directly to cancer cells for patients with advanced or recurrent endometrial cancer moves ahead to be studied further in a ...
As GSK races to match its PD-1 blocking antibody Jemperli to Merck’s superstar Keytruda, new pivotal data could help it expand into a broader endometrial cancer population. Jemperli, used on top of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The addition of pembrolizumab to chemotherapy as ...
A multicentre phase 2 study of carboplatin (C) plus pegylated liposomal doxorubicin (PLD) as first-line chemotherapy for patients (pts) with advanced or recurrent endometrial carcinoma (AEC): The ...
Merck’s blockbuster PD-1 inhibitor pembrolizumab (Keytruda) may be effective against endometrial cancer in some settings, but a statement today from the company shows that’s not so for all settings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results